Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer

Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial

NCT06282536 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

NCT01362296 ·Status: COMPLETED ·Phase: PHASE2

Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC

NCT07120282 ·Status: RECRUITING ·Phase: PHASE2

10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00004238 ·Status: COMPLETED ·Phase: PHASE2

A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

NCT03285763 ·Status: COMPLETED ·Phase: PHASE4

Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer

NCT04836728 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma

NCT04310943 ·Status: COMPLETED ·Phase: PHASE2

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

NCT00932893 ·Status: COMPLETED ·Phase: PHASE3

Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00005646 ·Status: COMPLETED ·Phase: PHASE2

LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer

NCT02328105 ·Status: COMPLETED ·Phase: PHASE2

A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer

NCT03472053 ·Status: COMPLETED ·Phase: PHASE2

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

NCT01970865 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC

NCT03668496 ·Status: UNKNOWN ·Phase: PHASE3

Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody

NCT03282435 ·Status: UNKNOWN ·Phase: PHASE1

T138067 in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous Chemotherapy

NCT00022243 ·Status: UNKNOWN ·Phase: PHASE2

Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer

NCT02250326 ·Status: COMPLETED ·Phase: PHASE2

Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

NCT00068289 ·Status: COMPLETED ·Phase: PHASE2

A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.

NCT00269828 ·Status: TERMINATED ·Phase: PHASE3

Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

NCT02132884 ·Status: TERMINATED ·Phase: NA

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

NCT06598306 ·Status: RECRUITING ·Phase: PHASE1

Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer

NCT04013542 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

NCT05334329 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00006929 ·Status: COMPLETED ·Phase: PHASE2

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

NCT02604342 ·Status: COMPLETED ·Phase: PHASE3

Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK

NCT05266846 ·Status: RECRUITING ·Phase: PHASE2